|
GENERIC
|
Latanoprostene bunod 0.024%
|
|
INDICATIONS
|
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
|
|
MECHANISM OF ACTION
|
Increasing aqueous outflow
|
|
MICROBIOLOGY
|
prostaglandin / nitric oxide (NO)-donor | Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
|
|
CONTRAINDICATIONS & WARNINGS
|
Increase in pigmentation of the iris and periorbital tissues, increase in length of eyelashes, intraocular inflammation, macular edema. Contact lenses should be removed 15 minutes prior to instillation of Vyzulta
|
|
PEDIATRIC USE
|
Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
|
|
PREGNANCY
|
There are no available human data for the use of VYZULTA during pregnancy to inform any drug associated risks.
|
